中文名称: | Pivanex | ||||
---|---|---|---|---|---|
英文名称: | Pivanex | ||||
别名: | AN-9; Pivalyloxymethyl butyrate | ||||
CAS No: | 122110-53-6 | 分子式: | C10H18O4 | 分子量: | 202.25 |
CAS No: | 122110-53-6 | ||||
分子式: | C10H18O4 | ||||
分子量: | 202.25 |
基本信息
产品编号:P10839 |
|||||
产品名称:Pivanex |
|||||
CAS: |
122110-53-6 |
储存条件 |
粉末 |
-20℃ |
四年 |
分子式: |
|||||
分子量 |
202.25 |
||||
化学名: |
|||||
Solubility (25°C) |
体外 |
DMSO |
≥100mg/mL (494.44mM) |
||
Ethanol |
|
||||
Water |
|
||||
体内 |
现配现用 |
|
|||
<1mg/ml表示微溶或不溶。 |
|||||
普西唐提供的所有化合物浓度为内部测试所得,实际溶液度可能与公布值有所偏差,属于正常的批间细微差异现象。 |
|||||
请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;⼀旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 |
制备储备液
浓度
溶液体积 质量 |
1mg |
5mg |
10mg |
1mM |
4.9444mL |
24.7219mL |
49.4438mL |
5mM |
0.9889mL |
4.9444mL |
9.8888mL |
10mM |
0.4944mL |
2.4722mL |
4.9444mL |
生物活性
产品描述 |
丁酸的衍生物,是口服有效的 HDAC 抑制剂。Pivanex 可下调 bcr-abl 蛋白,增强凋亡 (apoptosis)。 |
||
靶点/IC50 |
HDAC |
Bcr-Abl |
|
体外研究 |
Pivanex (100-500μM) exhibits significant anti-proliferation activity in K562 cells. Pivanex (100-500μM) also enhances apoptosis and caspase activity in K562 cells. Pivanex (200μM) induces enhancement in the G2-M phase, a moderate enhancement in the S phase and a slight reduction in G0-G1 of the cell cycle. Pivanex (AN-9) has selective toxicity to acute leukemia and drug-resistant primary leukemia and cancer cell lines. Cell Viability Assay |
||
Cell Line: |
K562 cells. |
||
Concentration: |
100-500μM. |
||
Incubation Time: |
24 hours. |
||
Result: |
Reduced the number of K562 viable cells significantly. 100μM Pivanex with 0.125 or 0.25μM STI571 reduced the number of viable cells synergistically. |
||
Apoptosis Analysis |
|||
Cell Line: |
K562 cells. |
||
Concentration: |
100-500μM. |
||
Incubation Time: |
6-72 hours. |
||
Result: |
Increased the number of K562 apoptotic cells significantly. Increased the caspase activity in K562 cells significantly after only 4 h of incubation with 500μM. |
||
体内研究 |
Pivanex (AN9, 200mg/kg, b.i.d, daily) significantly improves the survival of SMN7 SMA mice. Pivanex (AN9) treatment also marked delays the end stage of disease as defined by the onset of body mass loss. |
||
Animal Model: |
SMN7 SMA mice (SMN2+/+; SMN7+/+; mSmn−/−) [3] . |
||
Dosage: |
200mg/kg. |
||
Administration: |
Oral administration, b.i.d, at 09.00 and 17.00 daily |
||
Result: |
Improved the mean lifespan of treated SMN7 SMA mice by 84.6%.Delayed the onset of body mass loss in SMN7 SMA mice by 94.9%. |
本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:
质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)
摩尔浓度计算公式
用本工具协助配置特定浓度的溶液,使用的计算公式为:
开始浓度 x 开始体积 = 最终浓度 x 最终体积
稀释公式
稀释公式一般简略地表示为:C1V1 = C2V2 ( 输入 输出 )